Kiora Pharmaceuticals
KPRX
12 hedge funds and large institutions have $22.4M invested in Kiora Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
164% more capital invested
Capital invested by funds: $8.47M → $22.4M (+$13.9M)
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
33% more funds holding
Funds holding: 9 → 12 (+3)
0.01% more ownership
Funds ownership: 0.16% → 0.17% (+0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$1.77M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$182K |
| 3 |
Renaissance Technologies
New York
|
+$177K |
| 4 |
BlackRock
New York
|
+$142K |
| 5 |
VF
Virtu Financial
New York
|
+$69.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GSWM
Golden State Wealth Management
Santa Ana,
California
|
-$6K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$3.88K |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $18M | – | – | – |
|
|
2
Hudson Bay Capital Management
Stamford,
Connecticut
| $3.29M | +$1.77M | +912 | New |
|
|
3
Geode Capital Management
Boston,
Massachusetts
| $337K | +$182K | +94 | New |
|
|
4
Renaissance Technologies
New York
| $329K | +$177K | +91 | New |
|
|
5
BlackRock
New York
| $262K | +$142K | +73 | New |
|
|
VF
6
Virtu Financial
New York
| $129K | +$69.9K | +36 | New |
|
7
US Bancorp
Minneapolis,
Minnesota
| $27K | – | – | – |
|
8
Royal Bank of Canada
Toronto,
Ontario, Canada
| $17K | +$5.82K | +3 | +150% |
|
|
LTFS
9
Ladenburg Thalmann Financial Services
Miami,
Florida
| $6K | – | – | – |
|
10
UBS Group
Zurich,
Switzerland
| $6K | +$1.94K | +1 | +100% |
|
|
11
Acadian Asset Management
Boston,
Massachusetts
| $5K | -$3.88K | -2 | -67% |
|
12
Morgan Stanley
New York
| $3K | – | – | – |
|
|
VFA
13
Valeo Financial Advisors
Carmel,
Indiana
| $1K | – | – | – |
|
|
GSWM
14
Golden State Wealth Management
Santa Ana,
California
| – | -$6K | -5 | Closed |
|
|
15
Victory Capital Management
San Antonio,
Texas
| – | -$1K | -1 | Closed |
|
KPRX Hedge Fund Activity: Q4 2019 in Review
12 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q4 2019, worth a combined $22.4M — up 164% from $8.47M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new KPRX positions and 2 closed out — a net gain of 3 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Hudson Bay Capital Management, opening a new position worth an estimated $1.77M. The largest seller was Golden State Wealth Management, exiting entirely with an estimated $6K sold.
- 12 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q4 2019, up from 9 in Q3 2019.
- Funds reported $22.4M of Kiora Pharmaceuticals stock for Q4 2019, up 164% quarter-over-quarter.
- 5 funds opened new Kiora Pharmaceuticals positions in Q4 2019 and 2 closed out, a net change of +3 holders.
- The largest Kiora Pharmaceuticals buyer in Q4 2019 was Hudson Bay Capital Management, an estimated $1.77M added.
- The largest Kiora Pharmaceuticals seller in Q4 2019 was Golden State Wealth Management, an estimated $6K sold.
Based on aggregated 13F filings for Q4 2019.